Episode

Episode 174 - Bruce Leuchter - President & CEO Neurvati

Podcast
The BioHub - by Avetix
Published
May 18, 2026
Duration seconds
2018
Processing state
not_requested
Canonical source
https://podcasters.spotify.com/pod/show/max-brennan4/episodes/Episode-174---Bruce-Leuchter---President--CEO-Neurvati-e3ji04c
Audio
https://anchor.fm/s/f0076084/podcast/play/120176204/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-18%2F424402608-44100-2-9cdd6df7297d7.mp3
JSON
/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-174-bruce-leuchter-president-ceo-neurvati
Markdown
/podcast/the-biohub-by-avetix-7252289/episode-174-bruce-leuchter-president-ceo-neurvati.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-174-bruce-leuchter-president-ceo-neurvati/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-174-bruce-leuchter-president-ceo-neurvati.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode of The BioHub Podcast, Max sits down with Bruce Leuchter, co-founder and CEO of Neurvati Neurosciences. Bruce’s career spans clinical neuroscience, psychiatry, investment banking, and biotech company building — giving him a uniquely broad perspective on the future of CNS drug development. Neurvati, a Blackstone Life Sciences portfolio company, is focused on identifying and advancing high-potential therapies for neurological and psychiatric disorders. In this conversation, we discuss the evolving neuroscience landscape, how to choose the right assets and modalities, the differences between public and private markets in neuro, and why building the right team is so critical in biotech. A thoughtful conversation about one of the most challenging — and exciting — areas in medicine.